404 related articles for article (PubMed ID: 19925417)
21. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.
Llovera RE; de Tullio M; Alonso LG; Leissring MA; Kaufman SB; Roher AE; de Prat Gay G; Morelli L; Castaño EM
J Biol Chem; 2008 Jun; 283(25):17039-48. PubMed ID: 18411275
[TBL] [Abstract][Full Text] [Related]
22. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
[TBL] [Abstract][Full Text] [Related]
23. Identification and functional characterization of a putative IDE, C28F5.4 (ceIDE-1), in Caenorhabditis elegans: Implications for Alzheimer's disease.
Haque R; Nazir A
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2454-2462. PubMed ID: 27443962
[TBL] [Abstract][Full Text] [Related]
24. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.
Qiu WQ; Walsh DM; Ye Z; Vekrellis K; Zhang J; Podlisny MB; Rosner MR; Safavi A; Hersh LB; Selkoe DJ
J Biol Chem; 1998 Dec; 273(49):32730-8. PubMed ID: 9830016
[TBL] [Abstract][Full Text] [Related]
25. The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design.
Tundo GR; Grasso G; Persico M; Tkachuk O; Bellia F; Bocedi A; Marini S; Parravano M; Graziani G; Fattorusso C; Sbardella D
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892174
[TBL] [Abstract][Full Text] [Related]
26. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.
Song ES; Juliano MA; Juliano L; Hersh LB
J Biol Chem; 2003 Dec; 278(50):49789-94. PubMed ID: 14527953
[TBL] [Abstract][Full Text] [Related]
27. Degradation of amylin by insulin-degrading enzyme.
Bennett RG; Duckworth WC; Hamel FG
J Biol Chem; 2000 Nov; 275(47):36621-5. PubMed ID: 10973971
[TBL] [Abstract][Full Text] [Related]
28. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ; Folstein MF
Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
[TBL] [Abstract][Full Text] [Related]
29. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
Pivovarova O; Höhn A; Grune T; Pfeiffer AF; Rudovich N
Ann Med; 2016 Dec; 48(8):614-624. PubMed ID: 27320287
[TBL] [Abstract][Full Text] [Related]
30. The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition.
Li P; Kuo WL; Yousef M; Rosner MR; Tang WJ
Biochem Biophys Res Commun; 2006 May; 343(4):1032-7. PubMed ID: 16574064
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the insulin inhibition of the peptidolytic activities of the insulin-degrading enzyme-proteasome complex.
Bennett RG; Hamel FG; Duckworth WC
Diabetes; 1997 Feb; 46(2):197-203. PubMed ID: 9000694
[TBL] [Abstract][Full Text] [Related]
32. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.
Vekrellis K; Ye Z; Qiu WQ; Walsh D; Hartley D; Chesneau V; Rosner MR; Selkoe DJ
J Neurosci; 2000 Mar; 20(5):1657-65. PubMed ID: 10684867
[TBL] [Abstract][Full Text] [Related]
33. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.
Ralat LA; Guo Q; Ren M; Funke T; Dickey DM; Potter LR; Tang WJ
J Biol Chem; 2011 Feb; 286(6):4670-9. PubMed ID: 21098034
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
Ciaccio C; Tundo GR; Grasso G; Spoto G; Marasco D; Ruvo M; Gioia M; Rizzarelli E; Coletta M
J Mol Biol; 2009 Feb; 385(5):1556-67. PubMed ID: 19073193
[TBL] [Abstract][Full Text] [Related]
35. Ubiquitin is a novel substrate for human insulin-degrading enzyme.
Ralat LA; Kalas V; Zheng Z; Goldman RD; Sosnick TR; Tang WJ
J Mol Biol; 2011 Feb; 406(3):454-66. PubMed ID: 21185309
[TBL] [Abstract][Full Text] [Related]
36. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
[TBL] [Abstract][Full Text] [Related]
37. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.
Maianti JP; McFedries A; Foda ZH; Kleiner RE; Du XQ; Leissring MA; Tang WJ; Charron MJ; Seeliger MA; Saghatelian A; Liu DR
Nature; 2014 Jul; 511(7507):94-8. PubMed ID: 24847884
[TBL] [Abstract][Full Text] [Related]
38. Structural and functional characterization of pathogenic non- synonymous genetic mutations of human insulin-degrading enzyme by in silico methods.
Shaik NA; Kaleemuddin M; Banaganapalli B; Khan F; Shaik NS; Ajabnoor G; Al-Harthi SE; Bondagji N; Al-Aama JY; Elango R
CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):517-32. PubMed ID: 24059301
[TBL] [Abstract][Full Text] [Related]
39. A neglected modulator of insulin-degrading enzyme activity and conformation: The pH.
Grasso G; Satriano C; Milardi D
Biophys Chem; 2015; 203-204():33-40. PubMed ID: 26025789
[TBL] [Abstract][Full Text] [Related]
40. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation.
Cordes CM; Bennett RG; Siford GL; Hamel FG
Biochem Pharmacol; 2009 Mar; 77(6):1064-73. PubMed ID: 19154729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
